Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity
Juan J. Miret(Dana-Farber Cancer Institute), Esra A. Akbay(Southwestern Medical Center)
Cited by 152
Related Papers
D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice
|Genes & Development|2014|86
Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden
|Cancer Cell|2023|52
Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2
|RePEc: Research Papers in Economics|2020|11